June 11, 2009 - Bioptics will demo its Core Vision Radiography System at the Society of Nuclear Medicine, June 13-17, 2009 in Toronto, Ontario. The company recently received 510K cleared to use Core Vision Radiography System in core biopsy analysis.

The Core VISION is the first specimen radiography system dedicated to analyzing core biopsy samples that has received 510K approval. The Core VISION is small, simple to operate and has been ergonomically designed to speed the workflow during biopsy procedures and the results can be readily viewed by various clinicians through their standard PACS network and offers the highest resolution of any product in its class. The Core VISION is radiation shielded, interlocked and can be readily deployed in stereotactic procedure rooms.

The Core VISION complements the company's range of specimen radiography products and is said to enhance workflow during core biopsy procedures at a very cost effective price.

For more information: www.bioptics-inc.com


Additional Content

News | Breast Biopsy Systems

July 7, 2021 — GE Healthcare announced the installation of Serena Bright in five hospitals and radiology centers around ...

Time July 07, 2021
arrow
News | Breast Imaging

January 4, 2021 — Hologic, Inc. announced it has completed the acquisition of SOMATEX Medical Technologies GmbH, a ...

Time January 04, 2021
arrow
News | Prostate Cancer

According to the American Cancer Society, approximately one in nine men will be diagnosed with prostate cancer in their lifetime. It’s both the second most common cancer and second most common cause of cancer death in American men. Early detection is critical and can increase a man’s chances of survival.

Time August 20, 2019
arrow
News | Biopsy Systems

Dune Medical Devices has just completed the first in-man cases for Smart Biopsy, its percutaneous soft tissue biopsy device which leverages the real-time tissue characterization capability of its radiofrequency (RF) spectroscopy technology.

Time March 29, 2019
arrow
Technology | Interventional Radiology

The U.S. Food and Drug Administration (FDA) cleared the Ion endoluminal system from Intuitive Surgical Inc. to enable minimally invasive biopsy in the peripheral lung.

Time February 20, 2019
arrow
Subscribe Now